1. Home
  2. SII vs IDYA Comparison

SII vs IDYA Comparison

Compare SII & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

HOLD

Current Price

$122.67

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$30.00

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SII
IDYA
Founded
2008
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.9B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SII
IDYA
Price
$122.67
$30.00
Analyst Decision
Hold
Strong Buy
Analyst Count
1
14
Target Price
$132.00
$49.67
AVG Volume (30 Days)
315.1K
829.6K
Earning Date
02-19-2026
02-13-2026
Dividend Yield
1.05%
N/A
EPS Growth
7.97
N/A
EPS
1.96
N/A
Revenue
$216,267,000.00
$214,834,000.00
Revenue This Year
$27.96
$2,688.43
Revenue Next Year
$4.65
N/A
P/E Ratio
$63.26
N/A
Revenue Growth
22.38
5377.66
52 Week Low
$39.33
$13.45
52 Week High
$143.00
$39.28

Technical Indicators

Market Signals
Indicator
SII
IDYA
Relative Strength Index (RSI) 55.46 35.03
Support Level $117.07 $31.81
Resistance Level $125.30 $33.63
Average True Range (ATR) 6.39 1.58
MACD -1.50 -0.32
Stochastic Oscillator 30.61 12.65

Price Performance

Historical Comparison
SII
IDYA

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: